CONNECT WITH US
Funding Tracker

Funding Tracker

Docterz raises Rs 5 crore from 35 investors to build AI tools for doctors and explore acquisitions

Indian Startup News – Funding logo

Published on

Add as a preferred source on Google
Docterz raises Rs 5 crore from 35 investors to build AI tools for doctors and explore acquisitions

Mumbai-based healthtech startup Docterz, which makes clinic management software for doctors, has raised Rs 5 crore from around 35 investors. Nearly 60% of the money came from doctors who use its platform.

Around 20 doctors who use the startup's platform collectively invested nearly Rs 3 crore, translating to an average contribution of approximately Rs 15 lakh per doctor. The remaining Rs 2 crore or so came from about 15 other investors, including Vineeta Singh, co-founder and CEO of SUGAR Cosmetics, and Avnish Anand, co-founder and former CEO of jewellery brand CaratLane. 

Docterz said it will use the funding to grow organically, look at acquisitions and build AI tools for doctors. It also wants to reach more independent practitioners, smaller clinics and healthcare organisations across India.

Founded over a decade ago by practising paediatrician Atish Laddad, Docterz is based in Mumbai. Laddad serves as CEO, while co-founder Shailesh Garg is its CTO. Laddad said the participation of doctors who use the platform was what set the funding round apart.

“What makes this funding round special for me is that around 20 doctors who use Docterz have chosen to invest in its future. They know the product, they have seen its evolution, and they understand the needs of the medical community,” Laddad said.

“As a paediatrician, I started Docterz because I understood the challenges doctors face while managing a practice,” he added.

“ One of the strongest signals for any business is when its customers are willing to invest their own money in it.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.